Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7381427 | ACLARIS | Seborrheic keratosis treatment |
Jun, 2022
(11 months ago) | |
US10098910 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(11 years from now) | |
US9980983 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(11 years from now) | |
US10493103 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(11 years from now) | |
US10729720 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(11 years from now) | |
US9675639 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Jul, 2035
(12 years from now) |
Market Authorisation Date: 14 December, 2017
Treatment: Treatment of seborrheic keratoses that are raised
Dosage: SOLUTION;TOPICAL
14
United States
3
Australia
2
China
2
Canada
2
Brazil
2
Singapore
2
Mexico
2
Japan
2
European Union
1
New Zealand
1
Korea, Republic of
1
Germany
1
Russia
1
Austria
1
Spain
1
Israel
1
Portugal
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic